Literature DB >> 24012245

Muscle specific kinase autoimmune myasthenia gravis in children: a case series.

Karen L Skjei1, Vanda A Lennon, Nancy L Kuntz.   

Abstract

We report clinical, neurophysiological and autoantibody profiles of 9 children presenting with fatigable weakness and MuSK autoantibody seropositivity. Eight were female, 3 were black; median onset age was 8 years. Diplopia or bulbar dysfunction were common presenting symptoms. Half of the patients experienced moderate to severe weakness of bulbar, facial and respiratory muscles (including exacerbations requiring mechanical ventilation). Muscle AChR antibodies were detected transiently in 2 patients but no other autoantibodies were detected. Clinical response to treatment was variable and incomplete. No thymic abnormalities were noted by CT or pathologically (3 underwent thymectomy). Electromyographic (EMG) abnormalities (decrement of compound muscle action potential amplitude during slow repetitive nerve stimulation and variation in individual motor unit potentials) were limited to clinically weak muscles. Single fiber EMG demonstrated abnormalities in an asymptomatic muscle in the single patient studied. As in adults, MuSK autoimmune MG presents more commonly in females, and weakness preferentially affects bulbar, facial and respiratory muscles. Morbidity is significant and responses to standard therapies are variable and incomplete. Neurophysiological confirmation is more challenging in children because testing of weak muscles (cranial nerve-innervated and respiratory) may require moderate sedation and monitoring.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune myasthenia gravis; Children; Electromyography; Muscle-specific kinase autoantibodies

Mesh:

Substances:

Year:  2013        PMID: 24012245     DOI: 10.1016/j.nmd.2013.07.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature.

Authors:  XiuShan Ge; CuiJie Wei; Hui Dong; YueHua Zhang; XinHua Bao; Ye Wu; DanYu Song; HongJun Hao; Hui Xiong
Journal:  Front Pediatr       Date:  2022-05-11       Impact factor: 3.569

3.  Treating muscle-specific kinase myasthenia gravis from the inside out.

Authors:  Maartje G Huijbers; Jan J G M Verschuuren
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.